Vildagliptin

• Background:

  Vildagliptin is a potent inhibitor of dipeptidyl peptidase IV (DPP IV), an enzyme that cleaves glucagon-like peptide 1 (GLP-1) (1). Delaying the degradation of GLP-1 extends the action of insulin and suppresses the release of glucagon which results in reduction in elevated blood glucose levels (hyperglycemia) (2). It is a clinically useful antidiabetic agent. Ameliorates cognitive deficits in streptozotocin-induced Alzheimers disease model (3). Displays protective effects on βcells by inhibition of ER stress in a mouse model (4). Clinically useful antidiabetic agent.

• Description:

  Anti-diabetic agent

• Product Name Alternative:

  (S) -1-[N- (3-hydroxy-1-adamantyl) glycyl]pyrrolidine-2-carbonitrile; LAF237

• UNSPSC:

  41116105

• Type:

  Inhibitor

• Source:

  Synthetic

• Field of Research:

  Neuroscience | Neurodegeneration | Alzheimer's Disease | Cardiovascular System | Atherosclerosis | Diabetes Associated

• Purity:

  >98% (HPLC) ; NMR (Conforms)

• Weight:

  0.005

• Format:

  White powder

• Solubility:

  May be dissolved in DMSO (45 mg/ml); or DMF (20 mg/ml); or ethanol (20 mg/ml)

• Molecular Formula:

  C17H25N3O2

• Molecular Weight:

  303.4

• Precautions:

  Not for use in humans. Not for use in diagnostics or therapeutics. For in vitro research use only.

• References & Citations:

  1. B Balas et al. J. Clin. Endocrinol. Metab. 2007 92:1249 2. B Ahren et al. J. Clin. Endocrinol. Metab. 2004 89:2078 3. J Kosaraju et al. J. Pharm. Pharmacol. 2013 65:1773 4. S Shimizu et al. J. Mol. Endocrinol. 2012 49:125

• CAS Number:

  274901-16-5